Israeli FemTech company MobileODT has released its next-generation VisualCheck Artificial Intelligence (AI) Algorithm for the screening of cervical cancer.

Using multiple AI algorithms, VisualCheck provides results in less than 60 seconds, with accuracy similar to that of leading experts.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company stated that the new technology has been integrated with pathology (biopsy) results as a ground truth, which will allow it to recognise patterns that may not normally be visible to the human eye.

Additionally, the algorithm incorporates human-annotated images.

The VisualCheck technology closely mirrors cervical cancer and pre-cancer distribution in patients.

It uses an extensive dataset of cervical images, which were collected from across the globe, in various clinical stages.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This helps to provide improved accuracy for the cancer screening process.

MobileODT CEO Leon Boston said: “This new and novel algorithm is a testament to our technological advances and abilities as a FemTech digital health company.

“These developments are bringing our technology to the forefront of women’s health.”

The new algorithm was evaluated in a clinical trial, and the initial results supported its use as a primary screening tool.

The study results will be presented at the EUROGIN Conference in Dusseldorf, Germany, this May.

Stanford University Emeritus of Obstetrics and Gynecology professor Paul Blumenthal said: “AI is the future of women’s health and I am a great believer in its potential to revolutionise cervical cancer prevention.

“The inclusion of biopsy-based images to the algorithm has increased the clinical validity of the results.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact